Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Abbott Laboratories (NYSE: ABT), an Illinois-incorporated healthcare company whose common shares are listed on the New York Stock Exchange. Through these filings, investors can review official disclosures on Abbott’s operations, governance, financial reporting practices and material corporate events.
Abbott’s SEC filings include periodic reports and current reports on Form 8-K. Recent 8-K filings describe matters such as the entry into an Agreement and Plan of Merger with Exact Sciences Corporation, under which a wholly owned Abbott subsidiary will merge with Exact Sciences, with Exact Sciences surviving as a direct, wholly owned subsidiary of Abbott subject to customary closing conditions. Another 8-K details a notice of a blackout period for certain employee benefit plans due to administrative changes, including recordkeeper, trustee and custodian transitions, and outlines related trading restrictions for directors and executive officers. Additional 8-K disclosures cover corporate governance updates, such as amendments to Abbott’s by-laws to change the size of the board of directors and the appointment of a new director, as well as announcements of quarterly financial results and the company’s use of non-GAAP financial measures.
On Stock Titan, each new Abbott filing from the SEC’s EDGAR system can be viewed alongside AI-powered summaries that explain key points in clear language. These summaries help readers quickly understand topics like merger terms, benefit plan blackout periods, board changes, or how management presents adjusted financial metrics, without having to parse every technical detail. Users can also review exhibits referenced in the filings, such as merger agreements, notices to directors and officers, and amended by-laws, to see the underlying legal documents.
For those tracking insider-related information, governance changes or major transactions, Abbott’s SEC filings offer an authoritative record of the company’s regulatory disclosures, while AI-generated insights on this page aim to make those documents more accessible and easier to interpret.
ABBOTT LABORATORIES executive Lisa D. Earnhardt, EVP and Group President, reported a tax-withholding disposition of 8,577 common shares on February 27, 2026. The shares were valued at $116.26 per share for tax purposes, and she held 90,407 shares directly after this transaction.
Abbott Laboratories executive Elizabeth C. Cushman reported two share dispositions. On March 2, she completed an open-market sale of 263 common shares at $115.58 per share, leaving her with 38,573 shares held directly.
On February 27, she disposed of 1,421 shares at $116.26 per share to cover tax obligations through a tax-withholding transaction, rather than a traditional sale. Both transactions involve Abbott common shares without par value and reflect routine insider activity by the company’s EVP, General Counsel and Secretary.
Abbott Laboratories EVP and CFO Philip P. Boudreau reported a tax-related share disposition. On February 27, 2026, 7,441 common shares were surrendered at $116.26 per share to cover tax withholding obligations, a non-open-market transaction. After this, he directly held 71,172 common shares and indirectly held 366 shares through a Profit Sharing Trust as of that date.
Abbott Laboratories Senior Vice President Eric Shroff reported equity awards that increase his direct holdings. He received an option for 44,821 shares at an exercise price of $0.00 and a grant of 10,873 common shares, both characterized as awards or other acquisitions.
The 10,873-share grant is a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program with a three-year term and no more than one-third vesting in any year, tied to a minimum return on equity target. The 44,821-share employee stock option, also under the 2017 program, becomes exercisable in annual increments of 14,940 shares on February 24, 2027 and February 24, 2028, and 14,941 shares on February 24, 2029.